2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow CIN1: new trials by email Literature Review of CIN1 trials Research Report on CIN1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1348 | 2021-09-15 | 2024-04-17 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
Condylomata Acuminata (2) · Papillomavirus Infections (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (1)
Communicable Diseases (2) · DNA Virus Infections (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Infections (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2)
Shanghai Bovax Biotechnology Co., Ltd. (2)
China (2)
Ting Huang (1)